ERBB2 L869R

CI-VAR-00002447Explore in graph →NP_004439.2:p.Leu869ArgNM_004448.3:c.2606T>GClinVar 431024 CIViC 2330 rs1131692237

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ERBB2 L869R	Neratinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID6173 A 54-year-old female with heavily pre-treated estrogen and progesterone receptor positive, ERBB2 nonamplified lobular metastatic breast carcinoma harboring ERBB2 L869R mutation exhibited almost comple… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
431024	Pathogenic	no assertion criteria provided	0	Lung adenocarcinoma	somatic	1	May 01, 2015	clinvar